Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury

Journal of Neurotrauma

Volumn 30, Issue 6, 2013, Pages 441-452

  Wu, Yongchao ^a,d   Satkunendrarajah, Kajana ^a   Teng, Yang ^b   Chow, Diana S L ^b   Buttigieg, Josef ^a,e   Fehlings, Michael G ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF HOUSTON   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e UNIVERSITY OF REGINA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

R 116; RILUZOLE; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; CERVICAL SPINAL CORD INJURY; CONTROLLED STUDY; CYTOSKELETON; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; EVOKED RESPONSE; EVOKED SOMATOSENSORY RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OPEN FIELD BEHAVIOR; RAT; SINGLE DRUG DOSE; TISSUE PRESERVATION; TREATMENT DURATION;

ANIMALS; CERVICAL VERTEBRAE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EVOKED POTENTIALS, SOMATOSENSORY; FEMALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RILUZOLE; SPINAL CORD INJURIES; TIME FACTORS;

EID: 84876270838     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2012.2622     Document Type: Article

References (39)

1. Sekhon LH, and Fehlings MG. (2001). Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine 26, S2-12.
2. Tator CH, and Fehlings MG. (1991). Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 75, 15-26.
3. Park E, Velumian AA, and Fehlings MG. (2004). The role of ex-citotoxicity in secondary mechanisms of spinal cord injury: A review with an emphasis on the implications for white matter degeneration. J Neurotrauma 21, 754-774.
4. Tator CH, Hashimoto R, Raich A, Norvell D, Fehlings MG, Harrop JS, Guest J, Aarabi B, and Grossman RG. (2012). Translational potential of preclinical trials of neuroprotection through pharmacother-apy for spinal cord injury. J Neurosurg Spine 17, 157-229.
5. Schwartz G, and Fehlings MG. (2002). Secondary injury mechanisms of spinal cord trauma: A novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. In: Progress in Brain Research. L. McKerracher, G. Doucet, S. Rossignol (eds), Elsevier Science B.V., pps. 177-190.
6. Miller RG, Mitchell JD, Lyon M, and Moore DH. (2003). Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 4, 191-206.
7. Azbill RD, Mu X, and Springer JE. (2000). Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res 871, 175-180.
8. Doble A. (1996). The pharmacology and mechanism of action of ri-luzole. Neurology 47, S233-241.
9. Coderre TJ, Kumar N, Lefebrvre CD, and Yu JS. (2007). A comparison of the glutamate relase inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem 100, 1289-1299.
10. Springer JE, Azbill RD, Kennedy Se, George J, and Geddes JW. (1997). Rapid calpain I activation and cytoskeletal protein degradation following traumatic spinal cord injury: Attenuation with riluzole pretreatment. J Neurochem 69, 1592-1600.
11. Stutzman JM, Pratt J, Boraud T, and Gross C. (1996). The effect of riluzole on post-traumatic spinal cord injury in the rat. Neuroreport 7, 387-392.
12. Schwartz G, and Fehlings MG. (2001). Evaluation of the neuropro-tective effects of sodium channel blockers after spinal cord injury: Improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 94, 245-256.
13. Mu X, Azbill Rd, and Springer JE. (2000). Riluzole improves measure of oxidative stress following traumatic spinal cord injury. Brain Res 870, 66-72.
14. Ho Ch, Wuermser LA, Priebe MM, Chiodo AE, Scleza WM, and Kirshblum SC. (2007). Spinal cord injury medicine. 1. Epidemiology and classification. Arch Phys Med Rehabil 88, S49-54.
15. Krassioukov A. (2009). Autonomic function following cervical spinal cord injury. Respir Physiol Neurobiol 169, 157-164.
16. Fehlings MG, and Tator CH. (1995). The relationships among the severity of spinal cord injury, residual neurological function, axon counts, and counts of retrogradely labeled neurons after experimental spinal cord injury. Exp Neurol 132, 220-228.
17. Basso DM, Beattie MS, and Bresnahan JC. (1995). A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neu-rotrauma 12, 1-21.
18. Karimi-Abdolrezaee S, Eftekharpour E, Wang J, Morshead CM, and Fehlings MG. (2006). Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. J Neurosci 26, 3377-3389.
19. Karimi-Abdolrezaee S, Eftekharpour E, Wang J, Schut D, and Fehlings MG. (2010). Synergistic effects of transplanted adult neural stem-progenitor cells, chondroitinase, and growth factors promote functional repair and plasticity of the chronically injured spinal cord. J Neurosci 30, 1657-1676.
20. Bruce JC, Oatway MA, and Weaver LC. (2002). Chronic pain after clip-compression injury of the rat spinal cord. Exp Neurol 178, 33-48.
21. Oatway MA, Chen Y, Bruce JC, Dekaban GA, and Weaver LC. (2005). Anti-CD11d integrin antibody treatment restores normal se-rotonergic projections to the dorsal, intermediate, and ventral horns of the injured spinal cord. J Neurosci 25, 637-647.
22. Matsumoto H, Kumon Y, Watanabe H, Ohnishi T, Shudou M, Ii C, Takahashi H, Imai Y, and Tanaka J. (2007). Antibodies to CD11b, CD68, and lectin label neutrophils rather than microglia in traumatic and ischemic brain lesions. J Neurosci Res 85, 994-1009.
23. Baptiste DC, Austin JW, Zhao W, Nahirny A, Sugita S, and Fehlings MG. (2009). Systemic polyethylene glycol promotes neurological recovery and tissue sparing in rats after cervical spinal cord injury. J Neuropathol Exp Neurol 68, 661-667.
24. Millane A, Tortolano L, Fernandez C, Bensimon G, Meininger V, and Farinotti R. (2009). Brain and plasma riluzole pharmacoki-netics: effect of minocycline combination. J Pharm Pharm Sci 209-217.
25. Schumacher PA, Eubanks JH, and Fehlings MG. (1999). Increased calpain l-mediated proteolysis, and preferential loss of dephosphorylated NF200, following traumatic spinal cord injury. Neuroscience 91, 733-744.
26. Agrawal SK, and Fehlings MG. (1996). Mechanisms of secondary injury to spinal cord axons in vitro: role of Na +, Na(+)-K(+)-AT-Pase, the Na(+)-H+ exchanger, and the Na(+)-Ca2+ exchanger. J Neurosci 16, 545-552.
27. Stys PK. (2005). General mechanisms of axonal damage and its prevention. J Neurol Sci 233, 3-13.
28. Kretschmer BD, Kratzer U, and Schmidt WJ. (1998). Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn Schmiede-bergs Arch Pharmacol 358, 181-190.
29. Farber NB, Jiang XP, Heinkel C, and Nemmers B. (2002). Anti-epileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry 7, 726-733.
30. Palace J. (2008). Neuroprotection and repair. J Neurol Sci 265, 21-25.
31. Zarate CA, and Manji HK. (2008). Riluzole in psychiatry: A systematic review of the literature. Expert Opin Drug Metab Toxicol 4, 1223-1234.
32. McIntosh TK, Smith DH, Voddi M, Perri BR, and Stutzmann JM. (1996). Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat. J Neurotrauma 13, 767-780.
33. Agrawal SK, Theriault E, and Fehlings MG. (1998). Role of group I metabotropic glutamate receptors in traumatic spinal cord white matter injury. J Neurotrauma 15, 929-941.
34. Liu D, Thangnipon W, and McAdoo DJ. (1991). Excitatory amino acids rise to toxic levels upon impact injury to the rat spinal cord. Brain Res 547, 344-348.
35. Kwon BK, Stammers AM, Belanger LM, Bernardo A, Chan D, Bishop CM, Slobogean GP, Zhang H, Umedaly H, Giffin M, Street J, Boyd MC, Paquette SJ, Fisher CG, and Dvorak MF. (2010). Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma 27, 669-682.
36. Stammers AT, Liu J, and Kwon BK. (2012). Expression of inflammatory cytokines following acute spinal cord injury in a rodent model. J Neurosci Res 90, 782-790.
37. Metz GA, Merkler D, Dietz V, Schwab ME, and Fouad K. (2000). Efficient testing of motor function in spinal cord injured rats. Brain Res 883, 165-177.
38. Basso DM. (2004). Behavioral testing after spinal cord injury: Con-gruities, complexities, and controversies. J Neurotrauma 21, 395-404.
39. Rowland JW, Hawryluk GW, Kwon B, and Fehlings MG. (2008). Current status of acute spinal cord injury pathophysiology and emerging therapies: Promise on the horizon. Neurosurg Focus 25, E2.